

Haematologica
HAEMATOL/2019/238162
Version 3

Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial

Martine E.D. Chamuleau, Coreline N. Burggraaff, Marcel Nijland, Katerina Bakunina, Rogier Mous, Pieterella J. Lugtenburg, Daan Dierickx, Gustaaf W. van Imhoff, Joost S.P. Vermaat, Erik A.F. Marijt, Otto Visser, Caroline Mandigers, Yavuz M. Bilgin, Aart Beeker, Mark F. Durian, Bas van Rees, Lara H. Bohmer, Lidwine W. Tick, Rinske S. Boersma, Tjeerd J.F. Snijders, Harry C. Schouten, Harry R. Koene, Eva de Jongh, Nathalie Hijmering, Arjan Diepstra, Anke van den Berg, Anne I.J. Arens, Julia Huijbregts, Otto Hoekstra, Josee M. Zijlstra, Daphne de Jong, and Marie José Kersten

Disclosures: 1. This work was supported by Celgene [RV-CL-DLBCL-004414] who funded the research, provided lenalidomide free of charge, approved the original protocol and all amendments as written, but had no role in either the design of the study, the collection, analysis, and interpretation of the data, nor the preparation of the manuscript. The Dutch Cancer Society provided funding for the screening program and the clinical trial [EMCR 2014-7436]. 2. M.E.D.C. received institutional research funding from Gilead, Genmab, and BMS. M.N. received institutional research funding from Takeda and Nordic vector. R.M. received institutional research funding from Gilead, Takeda and reports consultancy for Takeda, Janssen Cilag, Abbvie, BMS, Celgene, MSD, Roche, and Sandoz. O.V. reports consultancy for Sanofi. P.J.L. received institutional research funding from Servier, Takeda and reports consultancy for Takeda, BMS, Celgene, Sandoz, Servier, Roche, Genmab. A.D. reports consultancy for Takeda. J.M.Z. received institutional research funding from Roche and Gilead and reports consultancy for Roche, Janssen, BMS, Takeda, Gilead, Mundipharma, and Karyopharm. M.J.K. received institutional research funding from Celgene and Roche and reports consultancy for Celgene and Roche. All other authors declare no competing interests. 3. Not applicable

Contributions: M.E.D.C., M.N., K.B., R.M., P.J.L., D.D., J.S.P.V., G.W.I., O.H., J.M.Z., D.J., and M.J.K. were involved in study design. M.E.D.C., M.N., R.M., P.L., D.D., E.A.F.M., J.V., O.V., C.M., Y.M.B., A.B., M.F.D, B.v.R., L.H.B, L.W.T, R.S.B, T.J.F.S, H.C.S., H.R.K, E.d.J., J.M.Z., and M.J.K. were involved in data collection, including patient accrual, enrolment, recruitment, and treatment. O.H., A.A. and J.H. were involved in reviewing scans. M.E.D.C., C.B., K.B., A.I.J.A., A.D., A.B., N.H., D.J. and M.J.K. were involved in data analysis and interpretation. The first draft of the manuscript was prepared by the first and last authors, and all authors contributed to revisions and approved the final manuscript.